Esophagus News

There were significant differences in percentages of children with eosinophilic esophagitis who experienced histologic remission with dupilumab compared with placebo, according to a study published in The New England Journal of Medicine.

Fewer ventilated patients who received pantoprazole, a widely available proton-pump inhibitor, experienced clinically important upper gastrointestinal bleeding, according to research published in the New England Journal of Medicine.

In a new clinical practice guideline, the AGA provides evidence-based recommendations for use of endoscopic eradication therapy in the management of Barrett’s esophagus, accounting for the presence of dysplasia and other scenarios.

WASHINGTON — In a Healio video exclusive, Carolyn Newberry, MD, discusses the importance of “personalized” lifestyle modifications, such as identifying dietary triggers and being mindful of meal-timing, for the management of GERD.

WASHINGTON — Among adults with eosinophilic esophagitis, weight gain while undergoing dietary therapy was associated with poor treatment response, regardless of baseline weight status, according to data presented at Digestive Disease Week.

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data.

WASHINGTON — Vonoprazan effectively relieved heartburn symptoms in patients with nonerosive reflux disease as early as day 1 of treatment, with results persisting after a 4-week placebo-controlled period through 20 weeks, according to data.

WASHINGTON — Swallowed corticosteroid treatment did not impact growth velocity among children with eosinophilic esophagitis, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

In this Healio video, David A. Johnson, MD, MACG, FASGE, MACP, reminds physicians to ask patients with nocturnal heartburn or GERD about associated sleep disturbances, which can negatively affect “next-day functioning” and quality of life.

More than 300 million people worldwide, including one in every 10 Americans, are living with a rare disease, yet these individuals and their families are often left isolated and without answers.